Pliant Therapeutics Inc Ordinary Shares PLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Trading Information
- Previous Close Price
- $0.70
- Day Range
- $0.66–0.71
- 52-Week Range
- $0.66–1.79
- Bid/Ask
- $0.68 / $0.69
- Shares Outstanding
- 61.99M
- Market Cap
- $42.97M
- Volume/Avg
- 999,035 / 395,701
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.pliantrx.com
Valuation
Metric | PLRX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.34 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PLRX
Financial Strength
Metric | PLRX |
|---|---|
Quick Ratio | 7.92 |
Current Ratio | 8.05 |
Interest Coverage | −711.63 |
Quick Ratio
PLRX
Profitability
Metric | PLRX |
|---|---|
Return on Assets (Normalized) | −33.36% |
Return on Equity (Normalized) | −43.28% |
Return on Invested Capital (Normalized) | −38.93% |
Return on Assets
PLRX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|gdWy$> | LOCK|J@>lD | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|v<@#q!# | LOCK|Jh?<# | $99B | |||
| Moderna Inc MRNA | LOCK|<M$Vt>F | LOCK|LY | $87B | |||
| argenx SE ADR ARGX | LOCK|HcJKt# | LOCK|w> | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|C$$nCm | LOCK|g^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|V&j>$^w | LOCK|%@#BF | $31B | |||
| Incyte Corp INCY | LOCK|&zqh<N | LOCK|BD^ | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|lYcWl^ | LOCK|>s<K< | $21B | |||
| BioNTech SE ADR BNTX | LOCK|lvlcyDj | LOCK|<c | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|f@&&v<$ | LOCK|^& | $15B |